Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Maughan

Showing results (31-40 of 111) with videos related to

Pageof 12
Sort By:
The Prostate|August 27, 2015
Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancerBenjamin L Maughan, Xian C Xhou, Daniel L Suzman, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 30, 2017
Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaborationNaoki Terada, Benjamin L Maughan, Shusuke Akamatsu, et al.
Journal of Geriatric Oncology|August 13, 2019
Patterns of treatment in metastatic renal cell carcinoma for older versus younger patientsAndrew W Hahn, John Esther, Benjamin Haaland, et al.
Urologic Oncology|April 23, 2020
<sup>18</sup>F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatmentJoseph M Armstrong, Christopher R Martin, Christopher Dechet, et al.
Prostate Cancer and Prostatic Diseases|January 6, 2018
p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancerBenjamin L Maughan, Liana B Guedes, Kenneth Boucher, et al.
The Oncologist|February 12, 2020
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell CarcinomaAndrew W Hahn, Charles Drake, Samuel R Denmeade, et al.
The Oncologist|March 7, 2024
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)Kamal Kant Sahu, Haoran Li, Vinay Mathew Thomas, et al.
Cancers|July 29, 2023
Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0Georges Gebrael, Kamal Kant Sahu, Beverly Chigarira, et al.
European Urology|August 19, 2025
The Role of Liquid Biopsy in the Management of Patients with Genitourinary MalignanciesBenjamin L Maughan, Lars Dyrskjøt, Petros Grivas, et al.
Cancers|November 14, 2023
Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural AreasHaoran Li, Kamal Kant Sahu, Shruti Adidam Kumar, et al.
Pageof 12

Showing results (31-40 of 111) with videos related to

Sort By:
Pageof 12
The Prostate|August 27, 2015
Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancerBenjamin L Maughan, Xian C Xhou, Daniel L Suzman, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 30, 2017
Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaborationNaoki Terada, Benjamin L Maughan, Shusuke Akamatsu, et al.
Journal of Geriatric Oncology|August 13, 2019
Patterns of treatment in metastatic renal cell carcinoma for older versus younger patientsAndrew W Hahn, John Esther, Benjamin Haaland, et al.
Urologic Oncology|April 23, 2020
<sup>18</sup>F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatmentJoseph M Armstrong, Christopher R Martin, Christopher Dechet, et al.
Prostate Cancer and Prostatic Diseases|January 6, 2018
p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancerBenjamin L Maughan, Liana B Guedes, Kenneth Boucher, et al.
The Oncologist|February 12, 2020
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell CarcinomaAndrew W Hahn, Charles Drake, Samuel R Denmeade, et al.
The Oncologist|March 7, 2024
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)Kamal Kant Sahu, Haoran Li, Vinay Mathew Thomas, et al.
Cancers|July 29, 2023
Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0Georges Gebrael, Kamal Kant Sahu, Beverly Chigarira, et al.
European Urology|August 19, 2025
The Role of Liquid Biopsy in the Management of Patients with Genitourinary MalignanciesBenjamin L Maughan, Lars Dyrskjøt, Petros Grivas, et al.
Cancers|November 14, 2023
Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural AreasHaoran Li, Kamal Kant Sahu, Shruti Adidam Kumar, et al.
Pageof 12